Form 4: Ultragenyx CFO Howard Horn Executes Stock Sale
Statement of Changes in Beneficial Ownership
Chief Financial Officer Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical Inc. common stock on May 1, 2026.
Summary
- Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., sold 4,683 shares of common stock.
- The transaction was executed at a price of $24.90 per share.
- The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
- Following the transaction, the reporting person retains beneficial ownership of 110,342 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted via a pre-planned 10b5-1 arrangement, which is standard practice for executive financial management.
Positives
- The transaction was executed under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.
Negatives
- The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.
Risks
- Continued insider selling can sometimes be perceived negatively by retail investors as a signal of management sentiment regarding future stock performance.
Future Outlook
No forward-looking guidance or operational outlook was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector, where executives frequently receive equity-based compensation and utilize these plans for liquidity and diversification purposes.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers in the pharmaceutical sector to ensure compliance with SEC regulations during stock divestment.
Stakeholder Impact
- Minimal impact expected as the transaction was pre-planned and represents a small portion of the executive's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/01/2026 | Date of the stock sale transaction. |
| 05/04/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Ultragenyx, RARE, Insider Trading, Form 4, CFO, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.